Document is current
Any future updates will be listed below
-
Authors
Centeno, Christopher J.
Fausel, Zachary
Dodson, Ehren
Berger, Dustin R.
Steinmetz, Neven J.
- License Information
-
More Information
Article History
Received: 18 December 2023
Accepted: 13 May 2024
First Online: 18 May 2024
Declarations
:
: The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the International Cellular Medicine Society Institutional Review Board (OHRP #IRB00002637, Approval number: ICMS-2013–0016, date: 04/22/2013). All patients signed informed consent before participating in the trial.
: Not applicable.
: One or more of the authors has declared a potential conflict of interest. ZF, ED, DRB, and NJS are or were previously employed by Regenexx, LLC. CJC is a shareholder, patent holder, and Chief Medical Officer of Regenexx, LLC and an owner of the Centeno-Schultz Clinic.
